- A new laboratory test predicts which of several cancer drugs will work best against a patient's tumor, and could become a powerful precision medicine tool for individualizing cancer therapy.
- New patients with cancer can now make an appointment to see an oncologist as soon as the following day at Dana-Farber/Brigham and Women's Cancer Center.
- A study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider — and offers a ready means of identifying them.
Tags: BreastCancer, OvarianCancer
- The Commission on Cancer has recognized the Dana-Farber/Brigham and Women's Cancer Center for its dedication to providing quality care to its patients and accorded it a three year accreditation.
- Scientists publish the first comprehensive catalog of genetic mutations and other abnormal changes found in 279 cancers of the head and neck, identifying several broken molecular pathways that might be targeted by existing and future cancer drugs.
Tags: BasicResearch, Genomics, HeadNeckCancers
- A new study finds many breast cancer patients don't know the characteristics of their own disease, such as cancer stage and tumor grade.
Tags: BreastCancer, PatientEducation
- Dana-Farber Cancer Institute is expanding its research footprint by moving into five floors at Longwood Center (360 Longwood Avenue), beginning later this month.
Tags: BasicResearch, TranslationalResearch
- A new study by Dana-Farber Cancer Institute investigators demonstrates that vitamin D can protect some people with colorectal cancer by perking up the immune system's vigilance against tumor cells.
Tags: ColonCancer, ImmuneSystem
- According to a new study led by Dana-Farber researchers, patients with metastatic colorectal cancer who had high levels of vitamin D in their bloodstream prior to treatment with chemotherapy and targeted drugs, survived longer, on average, than patients with lower levels of the vitamin.
Tags: BasicResearch, ColonCancer, Nutrition
Showing 1-10 of 570 items